Seres Therapeutics amends Vowst deal, secures USD 25 million milestone buyout from Nestlé Health Science

Seres Therapeutics Inc

Seres Therapeutics Inc

MCRB

0.00
  • Seres Therapeutics amended its VOWST asset sale agreement with Nestlé Health Science, exchanging potential future net sales milestones for USD 25 million.
  • Payment set in two USD 12.5 million installments on July 1, 2026, then Oct. 1, 2026.
  • Cash runway now projected well into Q1 2027, based on current operating plans.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seres Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606050700PRIMZONEFULLFEED9732311) on June 05, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.